Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/113559
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Aspirin in patients undergoing noncardiac surgery
Author: Devereaux, P.
Mrkobrada, M.
Sessler, D.
Leslie, K.
Alonso-Coello, P.
Kurz, A.
Villar, J.
Sigamani, A.
Biccard, B.
Meyhoff, C.
Parlow, J.
Guyatt, G.
Robinson, A.
Garg, A.
Rodseth, R.
Botto, F.
Buse, G.L.
Xavier, D.
Chan, M.
Tiboni, M.
et al.
Citation: New England Journal of Medicine, 2014; 370(16):1494-1503
Publisher: Massachusetts Medical Society
Issue Date: 2014
ISSN: 0028-4793
1533-4406
Statement of
Responsibility: 
P.J. Devereaux, M. Mrkobrada, D.I. Sessler, K. Leslie, P. Alonso-Coello, A. Kurz, J.C. Villar, A. Sigamani, B.M. Biccard, C.S. Meyhoff, J.L. Parlow, G. Guyatt, A. Robinson, A.X. Garg, R.N. Rodseth, F. Botto, G. Lurati Buse, D. Xavier, M.T.V. Chan, M. Tiboni, D. Cook, P.A. Kumar, P. Forget, G. Malaga, E. Fleischmann, M. Amir, J. Eikelboom, R. Mizera, D. Torres, C.Y. Wang, T. VanHelder, P. Paniagua, O. Berwanger, S. Srinathan, M. Graham, L. Pasin, Y. Le Manach, P. Gao, J. Pogue, R. Whitlock, A. Lamy, C. Kearon, C. Baigent, C. Chow, S. Pettit, S. Chrolavicius, and S. Yusuf, for the POISE-2 Investigators
Abstract: Background: There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both among patients who are already on an aspirin regimen and among those who are not. Methods: Using a 2-by-2 factorial trial design, we randomly assigned 10,010 patients who were preparing to undergo noncardiac surgery and were at risk for vascular complications to receive aspirin or placebo and clonidine or placebo. The results of the aspirin trial are reported here. The patients were stratified according to whether they had not been taking aspirin before the study (initiation stratum, with 5628 patients) or they were already on an aspirin regimen (continuation stratum, with 4382 patients). Patients started taking aspirin (at a dose of 200 mg) or placebo just before surgery and continued it daily (at a dose of 100 mg) for 30 days in the initiation stratum and for 7 days in the continuation stratum, after which patients resumed their regular aspirin regimen. The primary outcome was a composite of death or nonfatal myocardial infarction at 30 days. Results: The primary outcome occurred in 351 of 4998 patients (7.0%) in the aspirin group and in 355 of 5012 patients (7.1%) in the placebo group (hazard ratio in the aspirin group, 0.99; 95% confidence interval [CI], 0.86 to 1.15; P=0.92). Major bleeding was more common in the aspirin group than in the placebo group (230 patients [4.6%] vs. 188 patients [3.8%]; hazard ratio, 1.23; 95% CI, 1.01, to 1.49; P=0.04). The primary and secondary outcome results were similar in the two aspirin strata. Conclusions: Administration of aspirin before surgery and throughout the early postsurgical period had no significant effect on the rate of a composite of death or nonfatal myocardial infarction but increased the risk of major bleeding.
Keywords: Postoperative complications
Rights: Copyright © 2014 Massachusetts Medical Society. All rights reserved.
DOI: 10.1056/NEJMoa1401105
Grant ID: NHMRC
Published version: http://dx.doi.org/10.1056/nejmoa1401105
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.